Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Accured Expenses: 2014-2024

Historic Change in Accured Expenses for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $4.3 million.

  • Protagonist Therapeutics' Change in Accured Expenses rose 42.63% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 156.00%. This contributed to the annual value of $4.3 million for FY2024, which is 176.63% up from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Change in Accured Expenses is $4.3 million, which was up 176.63% from -$5.6 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Change in Accured Expenses ranged from a high of $19.1 million in FY2021 and a low of -$12.7 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$4.7 million, with a median of -$5.6 million in 2023.
  • In the last 5 years, Protagonist Therapeutics' Change in Accured Expenses spiked by 431.88% in 2020 and then plummeted by 166.58% in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Change in Accured Expenses (Yearly) stood at $5.8 million in 2020, then surged by 227.00% to $19.1 million in 2021, then slumped by 166.58% to -$12.7 million in 2022, then soared by 55.98% to -$5.6 million in 2023, then skyrocketed by 176.63% to $4.3 million in 2024.